Market Cap : 60.42 B | Enterprise Value : 69.25 B | PE Ratio : 72.76 | PB Ratio : 3.50 |
---|
NYSE:BSX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BSX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Boston Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $170 Mil. Boston Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $9,157 Mil. Boston Scientific's Total Stockholders Equity for the quarter that ended in Jun. 2022 was $17,252 Mil. Boston Scientific's debt to equity for the quarter that ended in Jun. 2022 was 0.54.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Boston Scientific's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Boston Scientific was 3.64. The lowest was 0.06. And the median was 0.56.
The historical data trend for Boston Scientific's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Boston Scientific's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Boston Scientific's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Boston Scientific's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (261 | + | 9190) | / | 16623 | |
= | 0.57 |
Boston Scientific's Debt to Equity Ratio for the quarter that ended in Jun. 2022 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (170 | + | 9157) | / | 17252 | |
= | 0.54 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Boston Scientific's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Wichmann David S | director | UNITEDHEALTH GROUP INC 9900 BREN RD E MINNETONKA MN 55343 |
Brown Vance R | officer: SVP, GC and Corp. Secretary | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Olson Scott | officer: SVP & Pres, Rhythm Management | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Scanlon Meghan | officer: SVP,Pres,Urology Pelvic Health | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Monson Jonathan | officer: VP, Corp Controller and CAO | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Fujimori Yoshiaki | director | 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
James Donna | director | ONE MIRANOVA PLACE SUITE 1040 COLUMBUS OH 43215 |
Zane Ellen M | director | C/O TUFTS-NEW ENGLAND MEDICAL CENTER 750 WASHINGTON STREET, TUFTS-NEMC #451 BOSTON MA 02111 |
Sununu John E | director | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Connors Nelda J | director | BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 |
Ludwig Edward J | director | C/O BECTON DICKERSON & CO 1 BECTON DR FRANKLIN LAKES NJ 07417 |
Roux David J | director | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Dockendorff Charles J | director | COVIDIEN LTD. 15 HAMPSHIRE STREET MANSFIELD MA 02048 |
Macmillan Stephen P | director | 250 CAMPUS DRIVE MARLBOROUGH MA 01752 |
Wang Xin Warren | officer: SVP and Pres, Asia Pacific | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
From GuruFocus
Other Sources
By Zacks 2022-03-04
By tipranks.com 2022-03-03
By Zacks 2022-01-26
By Zacks 2022-01-24
By Zacks 2021-12-16
By Zacks 2022-02-11
By tipranks.com 2022-03-23
By Zacks 2021-12-02
By tipranks.com 2022-02-11
By Zacks 2022-03-15
By Zacks 2022-02-02